Cerus Corporation (CERS) Gets Upgraded to Buy Post Q1 by BTIG

Cerus Corporation (NASDAQ:CERS) raised its full-year merchandise gross guidance scope to $227 cardinal – $231 million, reflecting 10% to 12% year-over-year increase. Management attributed the beardown commencement to 2026 to spot crossed the company’s business, successful peculiar owed to rising request for its INTERCEPT Fibrinogen Complex. Cerus Corporation (NASDAQ:CERS) besides announced a meaningful catalyst way successful 2026, spanning anticipated regulatory, clinical, and pipeline milestones, which includes ongoing INTERCEPT RBC regulatory reappraisal successful Europe, the Phase 3 RedeS readout successful the U.S., and the planned U.S. PMA submission for its caller INT200 illumination device.

Cerus Corporation (NASDAQ:CERS) is progressive successful the research, development, and manufacturing of biomedical and surgical products. The institution produces humor systems for platelets and plasma, operates done the Blood Safety segment, and markets products nether the INTERCEPT brand.

While we admit the imaginable of CERS arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 15 Stocks That Will Make You Rich successful 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey connected Google News.